Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

236 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Melanoma of unknown primary: New perspectives for an old story.
Boussios S, Rassy E, Samartzis E, Moschetta M, Sheriff M, Pérez-Fidalgo JA, Pavlidis N. Boussios S, et al. Among authors: moschetta m. Crit Rev Oncol Hematol. 2021 Feb;158:103208. doi: 10.1016/j.critrevonc.2020.103208. Epub 2020 Dec 28. Crit Rev Oncol Hematol. 2021. PMID: 33383207 Review.
Malignant peritoneal mesothelioma: clinical aspects, and therapeutic perspectives.
Boussios S, Moschetta M, Karathanasi A, Tsiouris AK, Kanellos FS, Tatsi K, Katsanos KH, Christodoulou DK. Boussios S, et al. Among authors: moschetta m. Ann Gastroenterol. 2018 Nov-Dec;31(6):659-669. doi: 10.20524/aog.2018.0305. Epub 2018 Sep 14. Ann Gastroenterol. 2018. PMID: 30386115 Free PMC article. Review.
The Developing Story of Predictive Biomarkers in Colorectal Cancer.
Boussios S, Ozturk MA, Moschetta M, Karathanasi A, Zakynthinakis-Kyriakou N, Katsanos KH, Christodoulou DK, Pavlidis N. Boussios S, et al. Among authors: moschetta m. J Pers Med. 2019 Feb 7;9(1):12. doi: 10.3390/jpm9010012. J Pers Med. 2019. PMID: 30736475 Free PMC article. Review.
BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population.
Turner NC, Alarcón E, Armstrong AC, Philco M, López Chuken YA, Sablin MP, Tamura K, Gómez Villanueva A, Pérez-Fidalgo JA, Cheung SYA, Corcoran C, Cullberg M, Davies BR, de Bruin EC, Foxley A, Lindemann JPO, Maudsley R, Moschetta M, Outhwaite E, Pass M, Rugman P, Schiavon G, Oliveira M. Turner NC, et al. Among authors: moschetta m. Ann Oncol. 2019 May 1;30(5):774-780. doi: 10.1093/annonc/mdz086. Ann Oncol. 2019. PMID: 30860570 Free PMC article. Clinical Trial.
PARP Inhibitors in Ovarian Cancer: The Route to "Ithaca".
Boussios S, Karathanasi A, Cooke D, Neille C, Sadauskaite A, Moschetta M, Zakynthinakis-Kyriakou N, Pavlidis N. Boussios S, et al. Among authors: moschetta m. Diagnostics (Basel). 2019 May 18;9(2):55. doi: 10.3390/diagnostics9020055. Diagnostics (Basel). 2019. PMID: 31109041 Free PMC article. Review.
236 results